Advanced therapy use and barriers to treatment escalation in RA patients with moderate disease activity in a large NHS Foundation Trust in South London, UK

Remicade (infliximab) - J&J

Humira (adalimumab) - AbbVie

Jyseleca (filgotinib) - Gilead

Rinvoq (upadacitinib) - AbbVie

Enbrel (etanercept) - Pfizer, Amgen

Aoibhinn Kelly1; Maddalena Rupnik2; Anna Andronache3; Nasra Ahmed1; Mrinalini Dey4; Elena Nikiphorou4, 5

May 23, 2026